IQVIA (NYSE:IQV) Issues FY 2025 Earnings Guidance

IQVIA (NYSE:IQV) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 11.700-12.100 for the period, compared to the consensus EPS estimate of 11.880. The company issued revenue guidance of $15.7 billion-$16.1 billion, compared to the consensus revenue estimate of $16.0 billion.

Analyst Ratings Changes

IQV has been the subject of a number of research analyst reports. Truist Financial cut their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stifel Nicolaus decreased their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $252.39.

IQVIA Trading Down 0.9 %

Shares of NYSE IQV traded down $1.83 during mid-day trading on Friday, hitting $208.13. The stock had a trading volume of 1,748,692 shares, compared to its average volume of 1,454,169. The business has a 50 day moving average price of $200.67 and a two-hundred day moving average price of $219.54. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market cap of $37.78 billion, a P/E ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts anticipate that IQVIA will post 10.81 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.